Marker Therapeutics, Inc. (MRKR) stock forecast & analysis
1.09
NasdaqCM · USDDelayed by 15 minutes
Down: -0.23, -17.4%
1.01Down: -0.08, -7.2%
1 analysis
Latest analysis: · verdict locked
- Open
- 1.34
- Previous close
- 1.32
- Day range
- 1.09 – 1.45
- 52-week range
- 0.8100 – 2.46
- Volume (shares)
- 1.90M
- Net assets
- Not available
- Expense ratio
- Not available
- Shares outstanding
- 16.67M
- P/E ratio
- Not available
- Dividend yield
- 0.00%
- Beta
- Not available
- Market cap
- 18.17M
Market Scanner’s AI analysis of Marker Therapeutics, Inc. (MRKR), updated November 2026: Marker Therapeutics' recent coverage focused on a significant CPRIT grant and a sharp price increase, alongside technical indicators.
This page is the public summary. A signed-in user can run a fresh five-stage AI analysis of Marker Therapeutics, Inc. (MRKR) and read the full verdict with the bull and bear debate behind it — using Market Scanner tokens, or their own OpenAI or Anthropic key.
Summary
Marker Therapeutics' recent coverage focused on a significant CPRIT grant and a sharp price increase, alongside technical indicators.
Recent analyses for MRKR covered a substantial $16.2 million grant from the Cancer Prevention and Research Institute of Texas to advance MT-601 into a Phase 2 study. This non-dilutive funding was noted as a potential runway extender. The stock experienced a significant price surge, closing at $1.32 after opening at $1.02 and trading between $0.98 and $1.68, representing a 55% gain from the prior session. Technical indicators such as the 50-day and 200-day moving averages were also examined.
MRKR news & sentiment
News coverage highlighted a significant non-dilutive grant award, which was seen as a positive development for extending the company's runway. Social media discussion was not covered in the provided notes.
MRKR technical picture
The stock closed at $1.32 following a significant 55% single-day gain on high volume. Momentum readings were mixed, with RSI elevated but MACD showing slight downward pressure. The price traded above its 50-day and 200-day moving averages, with the 50-day below the 200-day.
Fundamentals
The analysis covered Marker Therapeutics' market capitalization and share count, noting a lack of dividend payments. It also examined the stock's trading position relative to its 52-week range and its 50-day and 200-day moving averages, observing that the price had recently moved above the 200-day average.
Factors discussed — upside
- Awarded $16.2 million CPRIT grant for MT-601 Phase 2 study
- Grant funding is non-dilutive, potentially extending runway
- Significant single-day price increase of 55%
- Price trading above 50-day and 200-day moving averages
Factors discussed — risks
- 50-day moving average below 200-day moving average indicates prior downtrend structure
- Grant terms regarding disbursement schedule, co-funding, or milestones not disclosed
- Grant funding
- Price action
- Technical indicators
- Clinical development
Summary updated .
MRKR technical indicators
Common technical indicators for MRKR, computed from its daily closing prices.
| Indicator | Value | Reading |
|---|---|---|
| 50-day simple moving average | 1.03 | Price above |
| 10-day exponential moving average | 0.99 | Price above |
| Relative strength index (14-day) | 54.52 | Neutral |
| MACD line (12/26/9) | -0.0038 | Above its signal line |
| Bollinger bands (20-day, 2σ) | 0.74 – 1.17 | Price inside the bands |
Analyses
Recent MRKR.US analyses are locked — sign in to read them or generate a fresh one.
Locked
Unlock in the library — 1 newer report
Sign in to unlock the 2026-11-20 MRKR.US analysis
Get the verdict — free
Frequently asked questions
- What is the bull case for Marker Therapeutics, Inc.?
- The bull case for MRKR centers on a significant non-dilutive $16.2 million grant from CPRIT to advance MT-601, which could extend the company's runway. This was accompanied by a notable 55% single-day price increase, with the stock trading above key moving averages.
- What are the risks for Marker Therapeutics, Inc.?
- Risks for MRKR include the technical structure indicating a prior downtrend, as the 50-day moving average remains below the 200-day average. Additionally, details surrounding the grant's disbursement schedule and conditions were not disclosed.
- Is Marker Therapeutics, Inc. bullish or bearish?
- Recent AI analyses of Marker Therapeutics, Inc. examined factors on both sides. Discussed upside: The bull case for MRKR centers on a significant non-dilutive $16.2 million grant from CPRIT to advance MT-601, which could extend the company's runway. This was accompanied by a notable 55% single-day price increase, with the stock trading above key moving averages. Discussed risks: Risks for MRKR include the technical structure indicating a prior downtrend, as the 50-day moving average remains below the 200-day average. Additionally, details surrounding the grant's disbursement schedule and conditions were not disclosed. These are descriptive observations, not a recommendation.
- What is the latest sentiment on Marker Therapeutics, Inc.?
- News coverage highlighted a significant non-dilutive grant award, which was seen as a positive development for extending the company's runway. Social media discussion was not covered in the provided notes.
- How does Market Scanner analyse Marker Therapeutics, Inc.?
- Every analysis of Marker Therapeutics, Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.Read the methodology
What is the bull case for Marker Therapeutics, Inc.?
The bull case for MRKR centers on a significant non-dilutive $16.2 million grant from CPRIT to advance MT-601, which could extend the company's runway. This was accompanied by a notable 55% single-day price increase, with the stock trading above key moving averages.
What are the risks for Marker Therapeutics, Inc.?
Risks for MRKR include the technical structure indicating a prior downtrend, as the 50-day moving average remains below the 200-day average. Additionally, details surrounding the grant's disbursement schedule and conditions were not disclosed.
Is Marker Therapeutics, Inc. bullish or bearish?
Recent AI analyses of Marker Therapeutics, Inc. examined factors on both sides. Discussed upside: The bull case for MRKR centers on a significant non-dilutive $16.2 million grant from CPRIT to advance MT-601, which could extend the company's runway. This was accompanied by a notable 55% single-day price increase, with the stock trading above key moving averages. Discussed risks: Risks for MRKR include the technical structure indicating a prior downtrend, as the 50-day moving average remains below the 200-day average. Additionally, details surrounding the grant's disbursement schedule and conditions were not disclosed. These are descriptive observations, not a recommendation.
What is the latest sentiment on Marker Therapeutics, Inc.?
News coverage highlighted a significant non-dilutive grant award, which was seen as a positive development for extending the company's runway. Social media discussion was not covered in the provided notes.
How does Market Scanner analyse Marker Therapeutics, Inc.?
Every analysis of Marker Therapeutics, Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.
Read the methodology- Bundles used
- claude-medium-v2
Run a fresh MRKR.US analysis
Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.